Press Releases

WALTHAM, Mass. , Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other

- Data featured during oral session at the 62nd ASH Annual Meeting demonstrate deep, durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents - - Enrollment in pivotal AGAVE-201 trial on track to start by year-end - - Company to host conference call

WALTHAM, Mass. , Nov. 30, 2020 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring

WALTHAM, Mass. , Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W.

- Response rate of ~60% observed in patients following a median of five prior lines of treatment -   - Company to host conference call and webcast following oral presentation on Sunday, December 6, 2020 - WALTHAM, Mass. , Nov. 4, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc.

- Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021 -   - Company provides update on axatilimab development plan in cGVHD following recent FDA interactions; expects to commence pivotal trial by year-end -   - Data from Phase 1 trial

WALTHAM, Mass. , Oct. 26, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2020 financial

WALTHAM, Mass. , Sept. 2, 2020 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in

-- Emerging data for SNDX-5613 support several protocol enhancements to AUGMENT-101 to expand enrollment to pediatric patients and focus exclusively on patients with MLL-r and NPM1 mutant acute leukemias --   -- Recommended Phase 2 dose for AUGMENT-101 anticipated by year end; full Phase 1 data

WALTHAM, Mass. , Aug. 3, 2020 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate

WALTHAM, Mass. , July 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2020 financial

- Richard P. Shea to Retire as Chief Financial Officer - WALTHAM, Mass. , July 7, 2020 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the